Alector: Bleak Prospects After Alzheimer's Failure
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
FierceBiotech4d
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Alector turns to layoffs as Alzheimer’s drug fails
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
BioSpace4d
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector’s (ALEC) “Overweight” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...
ETF Daily News15h
What is HC Wainwright’s Estimate for Alector Q1 Earnings?
Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...
STAT4d
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
The Pharma Letter3d
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Fintel on MSN3d
Morgan Stanley Downgrades Alector (ALEC)
Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...
bovnews1d
Alector Inc (ALEC) Stock Rating Reduced by Morgan Stanley
On Wednesday, Alector Inc (ALEC) stock saw a decline, ending the day at $2.55 which represents a decrease of $-0.02 or -0.78% from the prior close of $2.57. The stock opened at $2.6 and touched a low ...